Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33

1. Openshaw PJ, Tregoning J, Harker J. RSV 2005: Global impact, changing concepts, and new challenges. Viral Immunol. 2005;18(4):749–51. Epub 2005/12/20. doi: 10.1089/vim.2005.18.749 16359242.

2. Centers for Disease Control and Prevention. RSV | Trends and Surveillance | Respiratory Syncytial Virus | CDC http://www.cdc.gov/rsv/research/us-surveillance.html2014 [updated Dec 4, 2014; cited 2015 4/10/2015]. Available from: http://www.cdc.gov/rsv/research/us-surveillance.html.

3. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108–19. doi: 10.1038/modpathol.3800725 17143259.

4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–86. 12517228.

5. Boyce TG, Mellen BG, Mitchel EF Jr., Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137(6):865–70. doi: 10.1067/mpd.2000.110531 11113845.

6. Cormier SA, You D, Honnegowda S. The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert review of anti-infective therapy. 2010;8(12):1371–80. doi: 10.1586/eri.10.125 21133663; PubMed Central PMCID: PMC3033119.

7. You D, Becnel D, Wang K, Ripple M, Daly M, Cormier SA. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respiratory research. 2006;7:107. doi: 10.1186/1465-9921-7-107 16893457; PubMed Central PMCID: PMC1563465.

8. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70. doi: 10.1038/nature08900 20200518; PubMed Central PMCID: PMC2862165.

9. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity. 2012;36(3):451–63. doi: 10.1016/j.immuni.2011.12.020 22425247.

10. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. The Journal of allergy and clinical immunology. 2012;129(1):191–8 e1–4. doi: 10.1016/j.jaci.2011.09.041 22079492.

11. Tulah AS, Holloway JW, Sayers I. Defining the contribution of SNPs identified in asthma GWAS to clinical variables in asthmatic children. BMC medical genetics. 2013;14:100. doi: 10.1186/1471-2350-14-100 24066901; PubMed Central PMCID: PMC3849932.

12. Akhabir L, Sandford A. Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases. Current genomics. 2010;11(8):591–606. doi: 10.2174/138920210793360907 21629437; PubMed Central PMCID: PMC3078684.

13. Faber TE, Schuurhof A, Vonk A, Koppelman GH, Hennus MP, Kimpen JL, et al. IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study. PloS one. 2012;7(5):e34364. Epub 2012/05/11. doi: 10.1371/journal.pone.0034364 22574108; PubMed Central PMCID: PMC3344820.

14. Bonnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP, Alves AC, et al. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. Nature genetics. 2013;45(8):902–6. doi: 10.1038/ng.2694 23817571.

15. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–8. doi: 10.1038/ni.2045 21623379; PubMed Central PMCID: PMC3417123.

16. Wang P, You D, Saravia J, Shen H, Cormier SA. Maternal exposure to combustion generated PM inhibits pulmonary Th1 maturation and concomitantly enhances postnatal asthma development in offspring. Particle and fibre toxicology. 2013;10(1):29.

17. Cormier SA, Shrestha B, Saravia J, Lee GI, Shen L, DeVincenzo JP, et al. Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol. 2014;88(16):9350–60. doi: 10.1128/JVI.00818-14 24920801; PubMed Central PMCID: PMC4136292.

18. Marr N, Wang TI, Kam SH, Hu YS, Sharma AA, Lam A, et al. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol. 2014;192(3):948–57. doi: 10.4049/jimmunol.1302007 24391215.

19. Naura AS, Hans CP, Zerfaoui M, You D, Cormier SA, Oumouna M, et al. Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2008;38(5):839–46. Epub 2008/02/12. doi: 10.1111/j.1365-2222.2008.02943.x 18261157; PubMed Central PMCID: PMC2740645.

20. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182(10):1305–14. doi: 10.1164/rccm.201002-0221OC 20622030; PubMed Central PMCID: PMC3001267.

21. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045–52. doi: 10.1136/thx.2009.121582 20581410.

22. Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, et al. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. The Journal of allergy and clinical immunology. 2009;123(4):964–6. doi: 10.1016/j.jaci.2008.12.011 19181372; PubMed Central PMCID: PMC2707077.

23. Hong JY, Bentley JK, Chung Y, Lei J, Steenrod JM, Chen Q, et al. Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells. The Journal of allergy and clinical immunology. 2014;134(2):429–39. Epub 2014/06/10. doi: 10.1016/j.jaci.2014.04.020 24910174; PubMed Central PMCID: PMC4119851.

24. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667–72. doi: 10.1164/rccm.200802-309OC 18565953; PubMed Central PMCID: PMC2556448.

25. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541–5. doi: 10.1016/S0140-6736(98)10321-5 10470697.

26. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95(4):500–5. 7700748.

27. Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. The Journal of allergy and clinical immunology. 2013;132(4):933–41. doi: 10.1016/j.jaci.2013.05.012 23810766.

28. Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425–35. Epub 2014/03/13. doi: 10.1016/j.immuni.2014.01.011 24613091; PubMed Central PMCID: PMC4210641.

29. Oliphant Christopher J, Hwang You Y, Walker Jennifer A, Salimi M, Wong See H, Brewer James M, et al. MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4+ T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion. Immunity. 2014. doi: 10.1016/j.immuni.2014.06.016

30. Murakami-Satsutani N, Ito T, Nakanishi T, Inagaki N, Tanaka A, Vien PT, et al. IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int. 2014;63(3):443–55. doi: 10.2332/allergolint.13-OA-0672 24851948.

31. Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol. 2011;41(6):1675–86. doi: 10.1002/eji.201041033 21469105.

32. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010;185(6):3472–80. doi: 10.4049/jimmunol.1000730 20693421.

33. Han J, Dakhama A, Jia Y, Wang M, Zeng W, Takeda K, et al. Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand. The Journal of allergy and clinical immunology. 2012;130(5):1175–86 e9. doi: 10.1016/j.jaci.2012.08.033 23036746; PubMed Central PMCID: PMC3593657.

34. McIntosh K. Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr. 1978;93(1):33–6. 650342.

35. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. The Journal of biological chemistry. 2007;282(36):26369–80. doi: 10.1074/jbc.M704916200 17623648.

36. Ohto-Ozaki H, Kuroiwa K, Mato N, Matsuyama Y, Hayakawa M, Tamemoto H, et al. Characterization of ST2 transgenic mice with resistance to IL-33. Eur J Immunol. 2010;40(9):2632–42. doi: 10.1002/eji.200940291 20662097.

37. Ho JE, Chen WY, Chen MH, Larson MG, McCabe EL, Cheng S, et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest. 2013;123(10):4208–18. doi: 10.1172/JCI67119 23999434; PubMed Central PMCID: PMC3784527.

38. Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med. 2008;178(11):1123–9. doi: 10.1164/rccm.200804-579OC 18776151; PubMed Central PMCID: PMC2588491.

39. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature reviews Immunology. 2010;10(2):103–10. doi: 10.1038/nri2692 20081870.

40. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2010;40(2):200–8. doi: 10.1111/j.1365-2222.2009.03384.x 19906013.

41. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90. doi: 10.1016/j.immuni.2005.09.015 16286016.

42. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(1):282–7. doi: 10.1073/pnas.0606854104 17185418; PubMed Central PMCID: PMC1765450.

43. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31(1):5–7. Epub 2009/07/17. doi: 10.1016/j.immuni.2009.06.011 19604486.

44. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(5):1673–8. Epub 2012/02/07. doi: 10.1073/pnas.1115884109 22307629; PubMed Central PMCID: PMC3277172.

45. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(22):9021–6. Epub 2009/05/15. doi: 10.1073/pnas.0812690106 19439663; PubMed Central PMCID: PMC2690027.

46. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84–98. Epub 2009/06/30. doi: 10.1016/j.immuni.2009.05.007 19559631.

47. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241–7. doi: 10.1038/ni.1703 19221555; PubMed Central PMCID: PMC2820724.

48. Zaiss MM, Maslowski KM, Mosconi I, Guenat N, Marsland BJ, Harris NL. IL-1beta suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS pathogens. 2013;9(8):e1003531. Epub 2013/08/13. doi: 10.1371/journal.ppat.1003531 23935505; PubMed Central PMCID: PMC3731249.

49. Huang H, Saravia J, You D, Shaw AJ, Cormier SA. Impaired gamma delta T cell-derived IL-17A and inflammasome activation during early respiratory syncytial virus infection in infants. Immunology and cell biology. 2014. doi: 10.1038/icb.2014.79 25267484.

50. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12(11):1055–62. doi: 10.1038/ni.2104 21909091.

51. Forsberg A, Bengtsson M, Eringfalt A, Ernerudh J, Mjosberg J, Jenmalm MC. GATA binding protein 3(+) group 2 innate lymphoid cells are present in cord blood and in higher proportions in male than in female neonates. The Journal of allergy and clinical immunology. 2014;134(1):228–30. doi: 10.1016/j.jaci.2014.01.027 24636083.

52. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191(6):1069–76. 10727469; PubMed Central PMCID: PMC2193113.

53. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f experiment Pathol u Pharmakol. 1931;162(4):480–3. doi: 10.1007/BF01863914

54. Saravia J, You D, Thevenot P, Lee GI, Shrestha B, Lomnicki S, et al. Early-life exposure to combustion-derived particulate matter causes pulmonary immunosuppression. Mucosal Immunol. 2013. doi: 10.1038/mi.2013.88 24172848.

55. Croghan C, Egeghy PP, editors. Methods of Dealing With Values Below the Limit of Detection Using SAS. Southern SAS User Group; 2003; St. Petersburg, FL: US-EPA.